MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.380
-0.120 (-8.00%)
Jun 5, 2026, 10:07 AM EDT - Market open
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,865,274
Market Cap
83.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Inovio Pharmaceuticals | 112 |
| MindWalk Holdings | 102 |
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| PolyPid | 75 |
| ImmuCell | 73 |
| Rani Therapeutics Holdings | 71 |
MAIA News
- 1 day ago - MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial - TheFly
- 1 day ago - MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - GlobeNewsWire
- 2 days ago - MAIA Biotechnology receives FDA clearance for amendment to IND application - TheFly
- 2 days ago - MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - GlobeNewsWire
- 3 days ago - MAIA Biotechnology announces open market purchases by CEO, director - TheFly
- 3 days ago - MAIA Biotechnology Announces Open Market Purchases by CEO and Director - GlobeNewsWire
- 4 days ago - MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology - GlobeNewsWire
- 14 days ago - MAIA Biotechnology Transcript: AGM 2026 - Transcripts